PeptideCompareEndoluten — EU research guide.
Endoluten is a Khavinson-series peptide bioregulator derived from the pineal-hypothalamic neuroendocrine complex, proposed to support circadian rhythmicity; however, a rat study of the related peptide AEDG found no effect on melatonin secretion in vitro. It is often marketed alongside Epitalon, since both are linked to the pineal gland from different angles — Epitalon synthetically, Endoluten as a natural tissue complex.
What is Endoluten?
Endoluten is a Khavinson-series peptide bioregulator derived from the pineal-hypothalamic neuroendocrine complex, proposed to support circadian rhythmicity; however, a rat study of the related peptide AEDG found no effect on melatonin secretion in vitro. It is often marketed alongside Epitalon, since both are linked to the pineal gland from different angles — Epitalon synthetically, Endoluten as a natural tissue complex.
What does the research show?
Available data is limited to animal and in-vitro studies of related peptides and unpublished manufacturer reports, all from the originating research group; no peer-reviewed human trial of Endoluten itself was found. As with Epitalon, most of the telomere- and longevity-related claims attached to this compound class come from the same limited research lineage rather than broad independent replication.
EU legal status
Not approved as a medicine anywhere in the EU. Available from a small number of specialist research vendors for laboratory use only.
Molecular information
Pharmacokinetics
Potency retained over time
Each line is one storage condition: it starts at 100% and falls as potency is lost. Above the dashed 80% line the material is considered reliable — hover for exact values.
⚠ A structural estimate, derived from each compound's sequence length, cyclisation and oxidation-, deamidation- and light-sensitive residues. Indicative only — not lab-measured per batch.
Endoluten is not yet in our price comparison
We expand EU supplier coverage every month.
References
- In-vitro rat study of synthetic AEDG (Epitalon), not of Endoluten: no significant effect on melatonin secretion at any age tested. It is a negative result for the melatonin claim, and it does not tell us anything about a tissue complex. Djeridane Y, Khavinson VKh, Anisimov VN, Touitou Y. Effect of a synthetic pineal tetrapeptide (Ala-Glu-Asp-Gly) on melatonin secretion by the pineal gland of young and old rats. J Endocrinol Invest. 2003;26(3):211-215. DOIPubMed 12809170
- Analytical paper from the Khavinson group that identifies AEDG in the polypeptide complex of the pineal gland. It is about composition, not clinical effect, and it does not name the commercial product Endoluten. Khavinson VKh, Kopylov AT, Vaskovsky BV, Ryzhak GA, Lin'kova NS. Identification of Peptide AEDG in the Polypeptide Complex of the Pineal Gland. Bull Exp Biol Med. 2017;164(1):41-43. DOIPubMed 29124531
- Group review of animal studies of peptide bioregulators (lifespan, tumour incidence). All data come from the originating group and its collaborators, and it does not evaluate Endoluten as a separate product. Khavinson VKh, Kuznik BI, Ryzhak GA. Peptide bioregulators: a new class of geroprotectors. Message 1: Results of experimental studies. Adv Gerontol. 2013;3(3):225-235. DOI
- Group review of clinical trials of seven peptide bioregulators. It lists the pineal extract Epithalamin but not Endoluten, so it does not provide human evidence for this compound; it is also a review by the developers. Khavinson VKh, Kuznik BI, Ryzhak GA. Peptide bioregulators: a new class of geroprotectors. Report 2: The results of clinical trials. Adv Gerontol. 2014;4(4):346-361. DOI
- Review of the group's lifespan and cancer-prevention studies in rodents and its long-term observations in people. Useful for context on the whole field, but written by the originators and not specific to Endoluten. Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. DOI